Genentech: Rozlytrek® (entrectinib) - Information for Patients What is ROZLYTREK ® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene
Entrectinib - Wikipedia Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors [5] It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 and anaplastic lymphoma kinase (ALK) [5]
Entrectinib (oral route) - Mayo Clinic Entrectinib is used to treat metastatic (lung cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a gene called ROS1
FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK, Genentech Inc ) for adults and pediatric patients 12 years of age and older with solid
Entrectinib - NCI - National Cancer Institute Entrectinib is approved to treat: Non-small cell lung cancer that is ROS1 positive It is used in adults whose cancer has spread to other parts of the body Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins
Entrectinib: an orally available, selective tyrosine kinase inhibitor . . . Entrectinib is a potent small-molecule tyrosine kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1, and ALK The consolidated results of 2 Phase I trials demonstrated activity in tyrosine kinase inhibitor-naïve patients along with substantial intracranial activity
Entrectinib Capsules: Uses Side Effects - Cleveland Clinic ENTRECTINIB (en TREK ti nib) treats some types of cancer It works by blocking a protein that causes cancer cells to grow and multiply This helps to slow or stop the spread of cancer cells
Rozlytrek (entrectinib): Uses, Side Effects, Dosage Reviews - GoodRx Rozlytrek (entrectinib) is a targeted therapy that treats metastatic non-small cell lung cancer (NSCLC) and many other advanced cancers that have specific mutations It’s a pill taken by mouth once a day, so it’s a convenient treatment option But it commonly causes tiredness, changes in taste, and constipation that can be bothersome